Literature DB >> 8201838

Type 1 reaction, neuritis and disability in leprosy. What is the current epidemiological situation?

C Lienhardt1, P E Fine.   

Abstract

Type 1 reaction is one of the major causes of nerve damage in leprosy patients leading to disabilities of varying severity. Though this complication of leprosy has been extensively described, we still know very little of its natural history and of the factors which may predispose to it. This paper examines the descriptive and analytic epidemiology of these reactions in leprosy. We find that they vary greatly in clinical expression, time of onset, duration and severity, which has important implications for the way they are handled in the context of leprosy-control programmes. We review the various risk factors that have been suggested over the last 30 years and the evidence of their utility in identifying 'high-risk' patients is assessed. We then review the specific aspects of neuritis and disability in leprosy and examine the contribution of Type 1 reaction to leprosy-associated disabilities. The prospects for early detection and prevention of Type 1 reaction are examined in the light of current knowledge, both at research and at the leprosy control level.

Entities:  

Mesh:

Year:  1994        PMID: 8201838     DOI: 10.5935/0305-7518.19940002

Source DB:  PubMed          Journal:  Lepr Rev        ISSN: 0305-7518            Impact factor:   0.537


  17 in total

1.  Reactions following completion of 1 and 2 year multidrug therapy (MDT).

Authors:  Ma Victoria F Balagon; Robert H Gelber; Rodolfo M Abalos; Roland V Cellona
Journal:  Am J Trop Med Hyg       Date:  2010-09       Impact factor: 2.345

Review 2.  Mycobacterium leprae-host-cell interactions and genetic determinants in leprosy: an overview.

Authors:  Roberta Olmo Pinheiro; Jorgenilce de Souza Salles; Euzenir Nunes Sarno; Elizabeth Pereira Sampaio
Journal:  Future Microbiol       Date:  2011-02       Impact factor: 3.165

3.  Reply to Zhang et al.: The differential role of LRRK2 variants in nested leprosy phenotypes.

Authors:  Vinicius M Fava; Aurélie Cobat; Chaïma Gzara; Alexandre Alcaïs; Laurent Abel; Erwin Schurr
Journal:  Proc Natl Acad Sci U S A       Date:  2020-04-28       Impact factor: 11.205

Review 4.  Recent advances in tropical medicine.

Authors:  D N Lockwood; G Pasvol
Journal:  BMJ       Date:  1994-06-11

5.  High levels of inflammatory cytokines are associated with poor clinical response to steroid treatment and recurrent episodes of type 1 reactions in leprosy.

Authors:  R Manandhar; N Shrestha; C R Butlin; P W Roche
Journal:  Clin Exp Immunol       Date:  2002-05       Impact factor: 4.330

6.  Immunohistological analysis of in situ expression of mycobacterial antigens in skin lesions of leprosy patients across the histopathological spectrum. Association of Mycobacterial lipoarabinomannan (LAM) and Mycobacterium leprae phenolic glycolipid-I (PGL-I) with leprosy reactions.

Authors:  C Verhagen; W Faber; P Klatser; A Buffing; B Naafs; P Das
Journal:  Am J Pathol       Date:  1999-06       Impact factor: 4.307

7.  Protein phosphorylation in human peripheral nerve: altered phosphorylation of a 25-kDa glycoprotein in leprosy.

Authors:  L M Suneetha; R J Korula; A S Balasubramanian
Journal:  Neurochem Res       Date:  1996-06       Impact factor: 3.996

8.  Dermoscopy in Leprosy: A Clinical and Histopathological Correlation Study.

Authors:  Alpana Mohta; Suresh Kumar Jain; Aditi Agrawal; Ramesh Kumar Kushwaha; Pritee Sharma; Khushboo Sethia; Manish Jain
Journal:  Dermatol Pract Concept       Date:  2021-04-12

9.  Leprosy: an overview of pathophysiology.

Authors:  Ramesh Marne Bhat; Chaitra Prakash
Journal:  Interdiscip Perspect Infect Dis       Date:  2012-09-04

10.  Leprosy--evolution of the path to eradication.

Authors:  Sunil Dogra; Tarun Narang; Bhushan Kumar
Journal:  Indian J Med Res       Date:  2013-01       Impact factor: 2.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.